BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
calcium channel activity
,
Lung cancer
,
Endothelial cell
,
Autoimmunity
,
Lipitor
,
VEGFA
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PD L1
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
ADM2
CXCL8
LINC-PINT
EGR1
ULBP1
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP
KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP
MURARO_PANCREAS_DUCTAL_CELL
KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_UP
HALLMARK_TNFA_SIGNALING_VIA_NFKB
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
CD8+ T cells from OT-1 mice after exposure to PD-L1
Colorectal cancer (HT29 & HCT116) and melanoma PES43 cells treated with Nivolumab, sPD-L1 or both
Explore Curated Studies Results
Literature
Most Relevant Literature
Expression and Prognostic Significance of PD-L1 and NY-ESO1 in Gallbladder Carcinoma.
Regeneration and rejuvenation of skin by a topical YAP activator.
Research progress in the regulation of tumor cell PD-L1 expression by N6-methyladenosine modificatio…
Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway:…
Machine learning predicts cancer subtypes and progression from blood immune signatures.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Effect of Chemotherapy on PD-L1 in NSCLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanom…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ